Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Inclusion Criteria:

* Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after resection for earlier stage disease is acceptable as long as patients are at least 6 months from surgery.
* Treatment plan includes a platinum-based doublet chemotherapy.
* ECOG 0, 1 or 2.
* Self-reported loss of body weight or anorexia.
* Serum C-reactive protein ≥5 mg/L.
* Life expectancy of at least 6 months.
* Adequate bone marrow, liver and renal function.
* Normal serum potassium.
* Ability to comply with the study requirements and give written informed consent.

Exclusion Criteria:

* Known physical or functional obstruction of the gastrointestinal tract, malabsorption, intractable vomiting, uncontrollable diarrhea, concurrently receiving tube feeding or parenteral nutrition, or unable to swallow investigational drug product.
* Concomitant therapy with an appetite stimulant.
* History of poorly controlled hypertension or congestive heart failure.
* Any implanted devices that could interfere with DXA scanning.
* Prolongation of QT interval.
* History of additional risk factors for torsades de pointe.
* Concomitant therapy with beta-adrenergic receptor antagonists (beta-blockers) or ergot derivatives.
* Females who are breast feeding, pregnant or of child-bearing potential who are not using adequate birth control.
* Any second malignancy which might confound the interpretation of safety or efficacy assessments.
* Any condition which increases the patient's risk for participating in the study.